If biotech companies in Brazil understand that they can use both plant variety and patent protection in certain cases, their ability to innovate may improve, says Gabriel Di Blasi of Di Blasi, Parente & Associados.
With discussions underway to create a CRISPR patent pool, Kevin O’Connor of Neal, Gerber & Eisenberg discusses the three main perspectives when considering the main benefits of such a move.
Inter partes reviews filed by generic drug companies have a higher institution rate but lower invalidation rate compared to other IPRs, say Wenhua Yu, Stephen Maebius and Tianran Yan of Foley & Lardner.
The patent system in the US and the EU is not rewarding complex research into treatments for a host of prevalent diseases and conditions, and reforms are going in the wrong direction, says Erika Lietzan of the University of Missouri School of Law.
The Brazilian Patent and Trademark Office has implemented several fast-track examination programmes. Ana Paula Jardim and Andréa Granthon of Luiz Leonardos report on the effectiveness of one of them, the Green Patent Programme.
A disagreement over how pharma patents in Brazil are examined seems to have come to an end, as Breno Souza, Luisa Rezende and Silvia Costa of Clarke Modet & Co Brazil report.
A new law on supplementary protection certificates will be implemented on April 1, with the application, prosecution and maintenance of SPCs taking centre stage. José Manuel González of Clarke, Modet & Co reports.
President Trump’s decision to pull the US out of the Trans-Pacific Partnership trade deal may have particularly pernicious consequences for the pharmaceutical and biotechnology industries, writes Kevin Noonan of McDonnell Boehnen Hulbert & Berghoff.
As securing patent eligibility for ‘healthcare IT’ applications seems to be becoming easier, companies looking to monetise IP in this area can breathe a sigh of relief. Stacy Taylor of DLA Piper explains more.
Anyone drafting patent licence agreements should follow several tips in order to avoid or better prepare for litigation later on, says Jessamyn Berniker of Williams & Connolly.